Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lung Neoplasms × tepotinib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1 Lung Neoplasms 1 Brain Neoplasms 1

Interventions

Radiotherapy 33 pembrolizumab 32 Cisplatin 32 Carboplatin 31 Pemetrexed 23 Paclitaxel 22 Docetaxel 17 Specimen Handling 16 Magnetic Resonance Spectroscopy 16 Gemcitabine 16 Nivolumab 15 Cyclophosphamide 14 osimertinib 13 Bevacizumab 13 Irinotecan 12 Etoposide 12 Erlotinib Hydrochloride 12 durvalumab 11 Radiation 11 Cetuximab 9 Topotecan 8 Immunoglobulin G 8 Disulfides 8 Celecoxib 8 fludarabine 7 Radiosurgery 7 Fluorouracil 7 Everolimus 7 Biopsy 7 atezolizumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05782361 2025-08-20

POTENT

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡